Our findings suggested pioglitazone had a therapeutic potential in improving fibrinolytic activity, and consequently preventing thromboembolic complications of diabetes and cardiovascular disease.”
“Objectives. The objectives of this study were to determine

the incidence of bad splits in sagittal split osteotomies (SSOs), performed at the same hospital, and if the occurrence was reduced over time because of technical progress and/or surgical experience. Bad splits were defined as buccal or lingual plate fractures.

Study design. The files of all patients (n = 1008) who underwent bilateral or unilateral SSO between October 1989 and October 2009 were reviewed retrospectively.

Results. A bad split occurred in 14 SSO sites (14 of 2005 sites). No bilateral bad splits occurred. There was no notable decrease of bad splits over

the 20 years. All bad splits were resolved perioperatively by plate-osteosynthesis without 3-deazaneplanocin A research buy the additional need of intermaxillary fixation. All patients with a bad split had a good and functional occlusion 6 months Aurora Kinase inhibitor postoperatively. No infections occurred at the site of the bad splits. No bad splits occurred in patients younger than 20 years. No particular type of dental-facial deformity, or skeletal class according to the Angle’s classification could be correlated with cases of bad splits as a predisposing risk factor.

Conclusion. Even if precautions are taken, a bad split can occur during SSO of the mandible. This complication is manageable because of its low incidence (0.7 % of all SSOs) and uneventful healing. A significant decrease in incidence did not occur during the 20-year period, and neither technical progress nor the surgeon’s experience further reduced the incidence of bad splits. (Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2010;110:430-435)”
“Background: Studies have demonstrated that patients with diets high in omega-3 fatty acids have a lower risk of adverse

cardiovascular events. C-reactive protein (CRP), a marker of inflammation, is a strong predictor of future cardiovascular events. omega-3 fatty acids have been shown to have anti-inflammatory properties. However, there is a paucity of data examining the effect of omega-3 fatty acids on CRP levels. This randomized, PFTα in vivo double-blind, placebo-controlled trial tested the hypothesis that treatment with omega-3 polyunsaturated fatty acids (n-3 PUFAs) would reduce serum high-sensitivity CRP levels. Materials & methods: Fifty three patients with elevated baseline CRP (>= 3 mg/l) were randomized to n-3 PUFA (27 patients) or placebo (26 patients). Patients with active infection, inflammatory disease, baseline CRP >= 10 mg/l or those started on HMG-CoA reductase inhibitor therapy during the study period were excluded. The primary end point was CRP level following 8 weeks of treatment. Results: After 8 weeks of treatment with the study drug, the median CRP level in the n-3 PUFA group was 3.4 mg/l compared with 4.0 mg/l in the placebo group (p = 0.36).